Agata Jarząb1, Jarogniew Łuszczki2, Małgorzata Guz1, Krystyna Skalicka-Woźniak3, Marta Hałasa1, Jolanta Smok-Kalwat4, Krzysztof Polberg5, Andrzej Stepulak6. 1. Department of Biochemistry and Molecular Biology, Medical University of Lublin, Lublin, Poland. 2. Department of Pathophysiology, Medical University of Lublin, Lublin, Poland. 3. Department of Pharmacognosy with Medical Plant Unit, Medical University of Lublin, Lublin, Poland. 4. Department of Clinical Oncology, Holy Cross Cancer Centre, Kielce, Poland. 5. Department of Otolaryngology, MSWiA Hospital, Lublin, Poland. 6. Department of Biochemistry and Molecular Biology, Medical University of Lublin, Lublin, Poland andrzej.stepulak@umlub.pl.
Abstract
BACKGROUND/AIM: Osthole is a simple coumarin that has been found to have anticancer, anti-inflammatory, antiviral, anticoagulant, anticonvulsant and antiallergic activities. The aim of this study was to analyze the combined anti-proliferative effect of cisplatin (CDDP) and osthole on a rhabdomyosarcoma cell line, and assess the pharmacology of drug-drug interaction between these drugs using isobolographic analysis. MATERIALS AND METHODS: The anticancer actions of osthole in combination with CDDP were evaluated using the tetrazolium dye-based MTT cell proliferation assay. RESULTS: Osthole and CDDP applied together augmented their anti-cancer activities and yielded an additive type of pharmacologic interaction by means of isobolographic analysis. CONCLUSION: Combined therapy using osthole and cisplatin could be suggested as a potential chemotherapy regimen against rhabdomyosarcoma. Copyright
BACKGROUND/AIM: Osthole is a simple coumarin that has been found to have anticancer, anti-inflammatory, antiviral, anticoagulant, anticonvulsant and antiallergic activities. The aim of this study was to analyze the combined anti-proliferative effect of cisplatin (CDDP) and osthole on a rhabdomyosarcoma cell line, and assess the pharmacology of drug-drug interaction between these drugs using isobolographic analysis. MATERIALS AND METHODS: The anticancer actions of osthole in combination with CDDP were evaluated using the tetrazolium dye-based MTT cell proliferation assay. RESULTS:Osthole and CDDP applied together augmented their anti-cancer activities and yielded an additive type of pharmacologic interaction by means of isobolographic analysis. CONCLUSION: Combined therapy using osthole and cisplatin could be suggested as a potential chemotherapy regimen against rhabdomyosarcoma. Copyright